Abstract: TH-PO1080
Diagnostic Accuracy and Prognostic Value of Urinary Soluble CD163 in Lupus Nephritis: A Systematic Review and Diagnostic Meta-Analysis
Session Information
- Pathology and Lab Medicine
October 22, 2026 | Location: Exhibit Hall A, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Pathology and Lab Medicine
- 1700 Pathology and Lab Medicine
Authors
- de Oliveira, Anita Nunes, Universidade Federal de Ciencias da Saude de Porto Alegre, Porto Alegre, RS, Brazil
- Aguiar, Pedro Emídio Goersch, Universidade Federal do Ceara, Fortaleza, CE, Brazil
- Babadopulos, Yasmin, Centro Universitario Christus, Fortaleza, CE, Brazil
- Alves, Mário, Universidade Federal do Ceara, Fortaleza, CE, Brazil
- Lima da Cruz Júnior, Jardeson, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil
- Oliveira Fonseca, Pandora Eloa, Universidade Federal de Campina Grande, Campina Grande, PB, Brazil
- Nunes, Ivana Sousa, Hospital Geral de Goiania Dr Alberto Rassi, Goiânia, GO, Brazil
- Albuquerque, Roxana De fátima camelo de, Universita degli Studi di Padova Scuola di Medicina e Chirurgia, Padua, Veneto, Italy
Background
Lupus nephritis (LN) is a major cause of morbidity and progression to end-stage renal disease (ESRD) in patients with systemic lupus erythematosus (SLE). Current biomarkers, including proteinuria and serological markers, have limited accuracy for detecting active renal inflammation and often fail to reflect intrarenal immune activity. Noninvasive biomarkers are therefore urgently needed.
Methods
We conducted a systematic review and diagnostic meta-analysis to evaluate the performance of uCD163 in detecting active LN. Pooled sensitivity, specificity, and diagnostic odds ratio (DOR) with 95% confidence intervals (CIs) were estimated using random-effects models, and overall diagnostic performance was assessed using summary receiver operating characteristic (SROC) analysis to obtain a pooled area under the curve (AUC). All statistical analyses were performed using the Rayyan software.
Results
We included eight studies with 1,110 participants. uCD163 demonstrated high diagnostic accuracy, with a pooled sensitivity of 0.89 (95% CI: 0.79–0.94) and specificity of 0.91 (95% CI: 0.81–0.96). The SROC analysis yielded an AUC of 0.93. The pooled DOR was 63.37 (95% CI: 14.25–281.75; p < 0.0001). Although heterogeneity was approximately 85% (I2 = 85%), no evidence of publication bias was detected.
Conclusion
uCD163 demonstrates high diagnostic accuracy for detecting active LN, with high sensitivity and specificity. Despite the presence of significant between-study heterogeneity, its overall performance supports its potential as a noninvasive biomarker for disease activity.